Lavanya Gurram

Lavanya Gurram

Auto-generated profile, based on publicly available information

Lavanya Gurram

Department of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
SMSamarpita Mohanty
Samarpita Mohanty
LGLavanya Gurram
Lavanya Gurram
SCSupriya Chopra
Supriya Chopra
UMUmesh Mahantshetty
Umesh Mahantshetty
SGSurbhi Grover
Surbhi Grover
PURPOSE: Chemoradiation remains a challenge in women living with HIV (WLWH) and cervical cancer primarily because of concerns regarding immune status. With limited literature available to help guide the management of these patients, clinical practices among oncologists are variable across India. Hence, we conducted a survey among radiation oncologists in India to assess the patterns of current practices of treating cervical cancer with chemoradiation in WLWH. MATERIALS AND METHODS: A questionnaire consisting of 12 questions related to the treatment of cervical cancer in WLWH was distributed to radiation oncologists at two national conferences in India. RESULTS: The questionnaire was distributed to 105 radiation oncologists, and 90 (85.7%) responses were received. 95.5% of respondents reported that patients with advanced cervical cancer constituted the majority of their practice. Chemoradiation was reported as the most common modality of planned treatment. Ninety-four percentage of respondents reported that they referred patients to an antiretroviral therapy clinic before starting definitive treatment. The majority of respondents (68%) do not plan for concurrent chemotherapy if CD4 counts were < 200 cells/mm3. As many as 50% of respondents reported that they would only start antiretroviral therapy when CD4 counts drop. Poor social support (37.6%), concurrent infections during treatment (28.2%), acute toxicities (21.2%), and poor nutrition (13%) were cited as the most common reasons for treatment interruption in cervical cancer patients with HIV. CONCLUSION: This survey highlights the prevalent inconsistencies in treatment protocols employed by radiation oncologists in India for the management of locally advanced cervical cancer in WLWH. It also reflects the need for social and nutritional support to help improve compliance and thereby improve outcomes in these patients.

15 September 2023 in Brachytherapy
Verified
Journal Article
Closed access
UMUmesh Mahantshetty
Umesh Mahantshetty
SKSheetal R. Kashid
Sheetal R. Kashid
GMGargee Mulye
Gargee Mulye
LGLavanya Gurram
Lavanya Gurram
REReena Engineer
Reena Engineer
SSS.K. Shrivastava
S.K. Shrivastava

24 March 2022 in JCO Global Oncology
Verified
Journal Article
Open access
LGLavanya Gurram
Lavanya Gurram
SMSamarpita Mohanty
Samarpita Mohanty
SCSupriya Chopra
Supriya Chopra
SGSurbhi Grover
Surbhi Grover
REReena Engineer
Reena Engineer
UMUmesh Mahantshetty
Umesh Mahantshetty
PURPOSE: There are limited data on management of cervical cancer in women living with HIV in the modern antiretroviral therapy era. The study aimed to evaluate outcomes and toxicities of these patients treated with radiotherapy. MATERIALS AND METHODS: A retrospective analysis of HIV-positive cervical cancer patients treated with radiotherapy between 2011 and 2018 was conducted at a tertiary care center in India. RESULTS: Eighty-two HIV-positive cervical cancer patients treated with radiotherapy were identified. Their median age was 45 years. Seventy-four (90%) patients received radiotherapy with curative-intent and eight patients received palliative radiotherapy. Median CD4 count at the start of treatment was 342 cells/mm3 (interquartile range: 241-531). Among patients planned for definitive radiotherapy, concurrent cisplatin was planned in 52 (70%) patients with a median of four chemotherapy cycles, and 81% (n = 60) patients received brachytherapy. Among patients who received brachytherapy, the median prescription dose was 80 Gy. Seventy-seven patients completed their prescribed treatment. At a median follow-up of 37 months, 3-year disease-free survival of patients planned with curative-intent was 54%. On multivariate analysis, treatment completion was associated with favorable disease-free survival. Grade III/IV acute gastrointestinal toxicity was seen in five (6.8%) patients, whereas 30% patients had grade III/IV acute hematologic toxicity. All these patients completed their planned radiotherapy with good supportive care. CONCLUSION: Standard treatment of chemoradiation should be planned in women living with HIV with well-managed HIV presenting with locally advanced cervical cancer. Our study highlights the need for optimal management of these patients by a multidisciplinary team with intensive supportive care to ensure completion of planned treatment to achieve better outcomes.

18 April 2024 in Brachytherapy
Verified
Journal Article
Closed access
SKSheetal R Kashid
Sheetal R Kashid
LGLavanya Gurram
Lavanya Gurram
SPSaritha Pullan
Saritha Pullan
SCSupriya Chopra
Supriya Chopra
PMPrachi Mittal
Prachi Mittal
UMUmesh Mahantshetty
Umesh Mahantshetty

1 December 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SSShashank Srinivasan
Shashank Srinivasan
LGLavanya Gurram
Lavanya Gurram
CJCarlton Johnny
Carlton Johnny
SCSupriya Chopra
Supriya Chopra
ADA. Dheera
A. Dheera
UMUmesh Mahantshetty
Umesh Mahantshetty

1 May 2021 in Brachytherapy
Verified
Journal Article
Closed access
SSSahil Sood
Sahil Sood
LGLavanya Gurram
Lavanya Gurram
DADheera Aravindakshan
Dheera Aravindakshan
JPJohn Paul
John Paul
SCSupriya Chopra
Supriya Chopra
UMUmesh Mahantshetty
Umesh Mahantshetty